Clover Health Investments, Corp. — Form 8-K Summary
Business Context and Reporting Period
Clover Health Investments, Corp. filed a Form 8-K reporting a Nasdaq continued-listing deficiency. The reported event occurred on April 2, 2024; the filing was signed on April 5, 2024. The filing does not report quarterly or annual operating results.
Financial Metrics and Liquidity
The filing provides no new information on revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Change Versus Prior Comparable Period
Nasdaq notified the Company that its Class A common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5450(a)(1). The notice had no immediate effect on the listing; the stock continued trading on the Nasdaq Global Select Market under the symbol CLOV.
Guidance, Outlook, Risks, and Unusual Items
- The Company has until September 30, 2024, to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days, subject to possible Nasdaq discretion regarding the required period.
- Management is monitoring the stock price and may consider options including seeking stockholder approval for a reverse stock split.
- If compliance is not regained, the Company may seek an additional 180-day compliance period by transferring its listing to the Nasdaq Capital Market, if eligible and if it satisfies applicable listing standards.
- Failure to regain compliance could result in a Nasdaq delisting determination. The Company could appeal such a determination to a Nasdaq hearing panel.
- There is no assurance that the Company will regain compliance, qualify for an additional compliance period, satisfy other Nasdaq requirements, or succeed in any appeal.
- The filing’s forward-looking statements regarding compliance, a potential transfer, appeal rights, and a possible reverse stock split are subject to the risks described in the Company’s Form 10-K filed March 14, 2024, and subsequent SEC filings.
Important Facts for Investors to Verify
- Whether CLOV’s closing bid price reaches and remains at or above $1.00 for the required period before September 30, 2024.
- Whether the Company seeks stockholder approval for, and implements, a reverse stock split.
- Whether the Company qualifies for and pursues a second compliance period through a potential transfer to the Nasdaq Capital Market.
- Any subsequent Nasdaq delisting notice, hearing-panel decision, or change in trading venue.
- The Company’s latest financial condition and risk factors in its March 14, 2024 Form 10-K and subsequent SEC filings.